For decades, KRAS mutations — drivers of roughly a third of all human cancers — were considered beyond the reach of medicine, a locked door in the architecture of disease. D3 Bio, a Shanghai-based biotechnology firm, arrives at the American Association for Cancer Research Annual Meeting in San Diego this April with five presentations and a quiet but consequential claim: that the door may be opening further. Their pipeline, centered on next-generation inhibitors targeting KRAS G12C and the more elusive G12D mutation, represents both the progress oncology has made and the distance still to trave
D3 Bio to Present KRAS Cancer Pipeline Data at AACR 2026 Conference
The pipeline targets KRAS-driven cancers affecting patients with advanced non-small cell lung cancer, colorectal cancer, and pancreatic cancer, addressing significant unmet medical needs in these patient populations.
KRAS mutations drive roughly one-third of all human cancers
Mark
Why does it matter that D3 Bio got two oral slots instead of just poster presentations?
Mimi
Oral presentations at AACR's plenary sessions are where the field pays closest attention. It means the conference organizers thought the data was significant enough to warrant live discussion, not just a poster board. That visibility shapes how oncologists and researchers think about the drug.
Mark
What's the actual difference between what Elisrasib does and what other KRAS G12C inhibitors already on the market do?
Mimi
The company emphasizes that Elisrasib binds more selectively and completely to the inactive form of the protein. Whether that translates to better outcomes in patients—fewer side effects, longer response times, better brain penetration—that's what the trial data will show. Right now it's a claim backed by lab work.
Mark
Why is D3S-003, the G12D inhibitor, getting so much attention from the company?
Mimi
Because G12D is the most common KRAS mutation in pancreatic cancer, and pancreatic cancer is one of the deadliest cancers we have. If you can make a drug that works against G12D, you're potentially opening a door for thousands of patients who have very few options.
Mark
The company mentions "overcoming resistance." What does that mean in plain terms?
Mimi
Patients respond well to KRAS G12C inhibitors initially, but their tumors adapt. Cancer cells find ways around the drug. D3S-002, the ERK inhibitor, is designed to block an escape route—a backup pathway the tumor might use. Used together, the two drugs might keep the cancer suppressed longer.
Mark
Is there any risk in presenting this data publicly before regulatory approval?
Mimi
There's always competitive risk—other companies see what you're doing and adjust their own strategies. But the biotech model depends on transparency with the scientific community. You need credibility and partnerships to move forward. Keeping data secret doesn't help you get to patients faster.
Le Pouls
- KRAS mutations have driven cancer in millions of patients for generations, yet effective treatments have existed for only a few years — and resistance to them emerges quickly, leaving patients with few options.
- D3 Bio secured two rare oral presentation slots at AACR 2026's most prominent clinical sessions, signaling that the scientific community considers their data worth the room's full attention.
- Elisrasib targets the KRAS G12C mutation with a mechanism designed to lock the cancer-driving protein in its inactive state, and early data spans both standalone use in lung cancer and combination therapy in colorectal and pancreatic cancers.
- A second drug, D3S-003, takes aim at KRAS G12D — a mutation far more common in pancreatic cancer but historically resistant to targeted therapy — using a dual-state binding approach meant to outmaneuver earlier inhibitors.
- Three additional poster presentations will expose early human trial data and pharmacokinetic modeling, giving investors, partners, and clinicians their first structured view of how D3 Bio's full pipeline holds up under scrutiny.
For decades, KRAS mutations — drivers of roughly a third of all human cancers — were considered beyond the reach of medicine, a locked door in the architecture of disease. D3 Bio, a Shanghai-based biotechnology firm, arrives at the American Association for Cancer Research Annual Meeting in San Diego this April with five presentations and a quiet but consequential claim: that the door may be opening further. Their pipeline, centered on next-generation inhibitors targeting KRAS G12C and the more elusive G12D mutation, represents both the progress oncology has made and the distance still to travel for patients with advanced lung, colorectal, and pancreatic cancers.
D3 Bio, a clinical-stage biotechnology company based in Shanghai, will present five studies at the American Association for Cancer Research Annual Meeting in San Diego this April — a gathering that functions as one of oncology's most consequential scientific forums. Two of those presentations earned oral slots in high-visibility plenary and mini-symposium sessions, a distinction that reflects genuine scientific interest in the company's approach to one of cancer biology's most stubborn problems: mutations in the KRAS gene.
At the center of D3 Bio's pipeline is Elisrasib, a next-generation inhibitor designed to target the KRAS G12C mutation. On April 19, the company will present phase 1/2 trial data on Elisrasib as a standalone treatment in patients with advanced non-small cell lung cancer, including some who have already received earlier KRAS inhibitors. Two days later, a second oral presentation will show how Elisrasib performs in combination with cetuximab in patients with metastatic colorectal and pancreatic cancers. The drug works by binding selectively to the inactive form of the KRAS G12C protein, locking it in an off state and disrupting the signaling that fuels tumor growth. Published studies have also documented its ability to penetrate the central nervous system.
Beyond Elisrasib, D3 Bio is developing two additional compounds that address different dimensions of the KRAS challenge. D3S-002 is an ERK1/2 inhibitor built for combination use, intended to enhance the effect of KRAS inhibitors and help counter the resistance that tends to develop over time. D3S-003 targets KRAS G12D — a mutation more prevalent in pancreatic and colorectal cancers and historically far harder to treat — using a dual-state binding mechanism designed to be more comprehensive than earlier approaches.
Three poster presentations will round out D3 Bio's presence at the conference, covering the first human trial of D3S-002, pharmacokinetic modeling for D3S-003, and preclinical potency data. Together, the five presentations offer the global oncology community its first detailed comparative look at D3 Bio's strategy. For patients living with advanced lung, colorectal, and pancreatic cancers — diseases where KRAS mutations are common and outcomes often poor — the April data represents one more measured step toward treatments that do not yet exist.
D3 Bio, a Shanghai-based biotechnology company, will take the stage at one of oncology's most prestigious gatherings this April with five presentations focused on a family of drugs designed to attack one of cancer's most stubborn targets: mutations in the KRAS gene. The American Association for Cancer Research Annual Meeting, running April 17-22 in San Diego, will feature two oral presentations from the company's pipeline—a distinction that signals the scientific community's interest in their work and marks a significant moment for a clinical-stage firm still proving its approach.
The centerpiece is Elisrasib, a next-generation inhibitor targeting KRAS G12C mutations. On Sunday, April 19, D3 Bio will present data from a phase 1/2 trial examining how the drug performs as a standalone treatment in patients with advanced non-small cell lung cancer, some of whom have already been treated with other KRAS G12C inhibitors. Two days later, they'll present additional results showing how Elisrasib works when combined with cetuximab in patients with metastatic colorectal and pancreatic cancers. Both presentations earned slots in high-visibility sessions—the Clinical Trials Plenary and the Clinical Trials Mini-Symposium—where the most significant clinical findings typically get discussed.
What makes Elisrasib distinct, according to the company's preclinical work, is its mechanism. The drug binds selectively to the inactive, GDP-bound form of KRAS G12C, effectively locking the protein in its off position and preventing the oncogenic signaling that drives tumor growth. Published research in Cancer Discovery and Nature Medicine has documented its potency and its ability to penetrate the central nervous system, a property that matters for certain brain tumors. The company is running global phase 2 trials across multiple cancer types carrying KRAS G12C mutations.
But Elisrasib is only part of the story. D3 Bio is also advancing two other drugs that address different angles of the KRAS problem. D3S-002 is an ERK1/2 inhibitor designed specifically for combination therapy—the idea being that it can work alongside KRAS inhibitors to enhance their effect and potentially overcome resistance that develops over time. D3S-003 tackles a different mutation entirely: KRAS G12D, which is far more common in pancreatic and colorectal cancers but has proven harder to drug. This compound binds both the inactive and active forms of the protein, a dual-state approach meant to cast a wider net than earlier generations of inhibitors.
Three additional presentations will appear as posters, the traditional format for earlier-stage data. One will detail the first human trial of D3S-002 in patients with advanced solid tumors carrying MAPK pathway mutations. Another will present pharmacokinetic modeling for D3S-003, the kind of foundational work that informs dosing and drug interactions. The third will showcase preclinical data on D3S-003's potency and selectivity.
George Chen, D3 Bio's founder and chief executive, framed the presentations as evidence of the company's scientific momentum and its commitment to addressing what remains a significant gap in cancer treatment. KRAS mutations drive roughly one-third of all human cancers, yet for decades they were considered undruggable. The first KRAS G12C inhibitors reached patients only in the past few years, and resistance emerges relatively quickly. The unmet need in KRAS G12D and other variants remains enormous, particularly in pancreatic cancer, where outcomes remain grim and treatment options limited.
The April presentations will give the global oncology community its first detailed look at how D3 Bio's approach compares to competitors already in the market. For investors and potential partners, the data will signal whether the company's scientific strategy is sound and whether its drugs might eventually reach patients. For the patients themselves—those living with advanced lung, colorectal, and pancreatic cancers—these presentations represent one more step in a long pipeline toward new options.
Citations marquantes
These presentations will showcase our comprehensive KRAS pipeline and our commitment to advancing transformative therapies for patients with KRAS-driven cancers.— George Chen, Founder, Chairman and CEO of D3 Bio
Envie de l'histoire complète ?
Lire l'original sur The Manila Times ↗
Health & Medicine